| 产品名称： | Y13-238 |
|---|---|
| 商品货号： | TS210634 |
| Organism： | Rattus norvegicus (B cell); Rattus norvegicus (myeloma), rat (B cell); rat (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | mixed, adherent and suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | sarcoma |
| Applications： | The antibody is specific for the Ha-ras (Harvey) p21 and does not react with the p21 of Ki-ras (Kirsten). |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Spleen cells were fused with 210RCY3 Ag 1.2.3 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against the p21 transforming protein encoded by the v-ras and c-ras (ras) oncogenes |
| Cellular Products： | immunoglobulin; monoclonal antibody; against the p21 transforming protein encoded by the v-ras and c-ras (ras) oncogenes |
| Comments： | Rats were immunized with syngeneic normal rat kidney cells (NRK) that had been infected with Harvey murine sarcoma virus. Spleen cells were fused with 210RCY3 Ag 1.2.3 myeloma cells. The antibody is specific for the Ha-ras (Harvey) p21 and does not react with the p21 of Ki-ras (Kirsten). |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Dislodge attached cells from the flask substrate with a cell scraper, aspirate and dispense into new flasks. Maintain cultures at a cell concentration between 1 x 105 and 1 x 106 cells/mL. Do not allow the cell concentration to exceed 1 x 106 cells/mL. Medium Renewal:Two to three times weekly |
| Cryopreservation： | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | IgG2a |
| Name of Depositor： | JR Stephenson, ME Furth |
| Deposited As： | rat (B cell); rat (myeloma) |
| References： | Furth ME, et al. Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family. J. Virol. 43: 294-304, 1982. PubMed: 6287003 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | Y13-238 |
|---|---|
| 商品货号： | TS210634 |
| Organism： | Rattus norvegicus (B cell); Rattus norvegicus (myeloma), rat (B cell); rat (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | mixed, adherent and suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | sarcoma |
| Applications： | The antibody is specific for the Ha-ras (Harvey) p21 and does not react with the p21 of Ki-ras (Kirsten). |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Spleen cells were fused with 210RCY3 Ag 1.2.3 myeloma cells. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against the p21 transforming protein encoded by the v-ras and c-ras (ras) oncogenes |
| Cellular Products： | immunoglobulin; monoclonal antibody; against the p21 transforming protein encoded by the v-ras and c-ras (ras) oncogenes |
| Comments： | Rats were immunized with syngeneic normal rat kidney cells (NRK) that had been infected with Harvey murine sarcoma virus. Spleen cells were fused with 210RCY3 Ag 1.2.3 myeloma cells. The antibody is specific for the Ha-ras (Harvey) p21 and does not react with the p21 of Ki-ras (Kirsten). |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Dislodge attached cells from the flask substrate with a cell scraper, aspirate and dispense into new flasks. Maintain cultures at a cell concentration between 1 x 105 and 1 x 106 cells/mL. Do not allow the cell concentration to exceed 1 x 106 cells/mL. Medium Renewal:Two to three times weekly |
| Cryopreservation： | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | IgG2a |
| Name of Depositor： | JR Stephenson, ME Furth |
| Deposited As： | rat (B cell); rat (myeloma) |
| References： | Furth ME, et al. Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family. J. Virol. 43: 294-304, 1982. PubMed: 6287003 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. |
